Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trastuzumab in Treating Women With Primary Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Breast International Group
European Organisation for Research and Treatment of Cancer - EORTC
NCIC Clinical Trials Group
International Breast Cancer Study Group
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00045032
First received: September 6, 2002
Last updated: June 4, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2015
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Publications:
McCaskill-Stevens W, Procter M, Goodbrand J, et al.: Disease-free survival according to local immunohistochemistry for HER2 and central fluorescence in situ hydridization for patients treated with adjuvant chemotherapy with and without trastuzumab in the HERA (BIG 01-01) trial. [Abstract] Breast Cancer Res Treat 106 (1): A-71, S18, 2007.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):